STOCK TITAN
  1. Home
  2. News
  3. NRXP

NRX Pharmaceuticals Inc - NRXP STOCK NEWS

Welcome to our dedicated news page for NRX Pharmaceuticals (Ticker: NRXP), a resource for investors and traders seeking the latest updates and insights on NRX Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NRX Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NRX Pharmaceuticals's position in the market.

News
NRx Pharmaceuticals (Nasdaq: NRXP) Demonstrates Compliance with Nasdaq MVLS Standard
Rhea-AI Summary
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has announced plans to achieve compliance with Nasdaq market requirements related to minimum bid price and total Market Value of Listed Securities. The company aims to present its full compliance plan to Nasdaq on January 4, 2024, based on achieving clinical and regulatory milestones. NRx has demonstrated compliance with the $35 million MVLS since Dec 18, 2023, and aims to maintain compliance with this requirement going forward, rendering NRXP eligible for a second 180-day compliance period to reach a bid price of $1.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.48%
Tags
none
-
News
NRx Pharmaceuticals Announces the Election of Janet Rehnquist to its Board of Directors
Rhea-AI Summary
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announces the election of Janet Rehnquist, former Inspector General of the US Dept. of Health and Human Services, to its Board of Directors. Ms. Rehnquist will chair the compliance and nominating committees, bringing her extensive experience in healthcare law and compliance matters to the company. NRx Pharmaceuticals is focused on developing drug treatments for urgent unmet medical needs in CNS and mental health, particularly suicidal depression.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.5%
Tags
management
-
News
NRx Pharmaceuticals Announces Signing of a Data and Technical Information Agreement with Columbia University Accessing Key Data Demonstrating Efficacy and Safety of Intravenous Ketamine for the Treatment of Suicidal Depression
Rhea-AI Summary
NRx Pharmaceuticals, Inc. (NRXP) announced the signing of a License Data and Technical Information Agreement with Columbia University for rights to data from a randomized, active-controlled trial of 80 patients hospitalized for Acute Suicidality in Depression. The trial demonstrated a rapid and statistically significant reduction in Suicidal Ideation (SSI) at day 1 (p=0.0003) and in depression (P=0.0234) among patients randomized to IV Ketamine compared to those randomized to midazolam. NRx plans to present the data from these two trials to FDA in support of a New Drug Application to be filed in q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.36%
Tags
none
News
NRx Pharmaceuticals Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections
Rhea-AI Summary
NRx Pharmaceuticals, Inc. (NRXP) receives FDA clearance for NRX-101 to treat complicated Urinary Tract Infections. The potential to initiate a registrational study in 2024, with the aim to develop and commercialize NRX-101 for cUTI. The company plans to spin out a new company for this initiative, with the manufacturing phase of NRX-101 complete, and Composition of Matter patent protection secured. Michael Manyak, MD, an internationally-recognized urologist, joins as Lead Clinical Advisor for the initiative.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.19%
Tags
clinical trial
-
News
NRx Pharmaceuticals Provides Notice of Annual Meeting of Shareholders
Rhea-AI Summary
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announced their 2023 Annual Meeting of Stockholders to be held on December 19, 2023, in virtual-only format. The meeting will address the election of Janet Rehnquist as a member of the Company's Board of Directors and the planned spinoff of the IV Ketamine focused company, Hope Therapeutics, Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.81%
Tags
none
-
News
NRx Pharmaceuticals to Participate in LifeSci Corporate Access Event
Rhea-AI Summary
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) will be participating in the LifeSci Partners Corporate Access Event from January 8th through the 10th in San Francisco. The company anticipates substantial growth in 2024, including the filing of its first New Drug Application. NRx Pharmaceuticals will update investors on recent progress, upcoming clinical and regulatory catalysts, and answer questions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
conferences
News
NRx Pharmaceuticals to Present at Noble Capital Markets' 19th Annual Emerging Growth Investor Conference
Rhea-AI Summary
NRx Pharmaceuticals, Inc. (NRXP) will be presenting a corporate overview at the Noble Capital Markets' 19th Annual Emerging Growth Investor Conference on December 4th, 2023. Dr. Jonathan Javitt, Founder and Chief Scientist, will deliver the presentation at Florida Atlantic University in Boca Raton, Fla. The event will include in-person one-on-one meetings with management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.42%
Tags
conferences acquisition
-
News
NRx Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announced four near-term milestones, including the completion of the Phase 2b/3 trial of NRX-101 in Treatment Resistant Bipolar Depression and initiation of potential spinout initiatives in 2023/early 2024. The company also opened an Investigational New Drug application with the FDA to treat chronic pain with NRX-101 and received data from randomized, controlled trials demonstrating safety and efficacy of IV ketamine in treating suicidal depression.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
earnings
-
News
NRx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 14, 2023
Rhea-AI Summary
NRx Pharmaceuticals, Inc. will release its third quarter 2023 financial results on November 14, 2023, and host a conference call to discuss the results and provide a corporate update. The updates are expected to cover progress on the development of NRX-101 for bipolar depression, clinical trial data timing, and plans for NRX-100 (ketamine) development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.48%
Tags
conferences earnings
News
NRx Pharmaceuticals and Nephron Pharmaceuticals Announce Joint Agreement to Develop Intravenous Ketamine to Treat Suicidal Depression
Rhea-AI Summary
NRx Pharmaceuticals and Nephron Pharmaceuticals have signed a development and manufacturing agreement to produce a tamper and diversion-resistant formulation of ketamine for treating suicidal depression. The partners aim to submit a New Drug Application by March 1, 2024, with a finished drug targeted for November 2024, pending FDA approval. Ketamine has shown promise in rapidly reducing suicidal thoughts, but no FDA-approved formulation currently exists for this purpose.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.18%
Tags
none
Stock NRXP logo
NRX Pharmaceuticals Inc

Nasdaq:NRXP

NRXP Rankings

#4974 Ranked by Market Cap
#4956 Ranked by Stock Gains
N/A Ranked by Dividends

NRXP Stock Data

49.00M
6.63M
30.04%
4.29%
4.44%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Delray Beach